Market Research Reports and Industry Reports

Global Big Pharma Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Global Big Pharma Partnering Terms and Agreements 2010 to 2016 report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Big Pharma deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Big Pharma deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Big Pharma agreements with real life case studies
Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
Identify most active Big Pharma dealmakers since 2010
Insight into terms included in a Big Pharma partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

Big Pharma Partnering Terms and Agreements includes:

Trends in Big Pharma dealmaking in the biopharma industry since 2010
Analysis of Big Pharma deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Big Pharma deals
Access to Big Pharma contract documents
Leading Big Pharma deals by value since 2010
Most active Big Pharma dealmakers since 2010

In Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 3,000 Big Pharma deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in Big Pharma dealmaking

2.1. Introduction
2.2. Big Pharma partnering over the years
2.3. Most active Big Pharma dealmakers
2.4. Big Pharma partnering by deal type
2.5. Big Pharma partnering by therapy area
2.6. Big Pharma partnering by technology type
2.7. Deal terms for Big Pharma partnering
2.7.1 Big Pharma partnering headline values
2.7.2 Big Pharma deal upfront payments
2.7.3 Big Pharma deal milestone payments
2.7.4 Big Pharma royalty rates

Chapter 3 Leading Big Pharma deals

3.1. Introduction
3.2. Top Big Pharma deals by value

Chapter 4 Most active Big Pharma dealmakers

4.1. Introduction
4.2. Most active Big Pharma dealmakers
4.3. Most active Big Pharma partnering company profiles
Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 Big Pharma contracts dealmaking directory

5.1. Introduction
5.2. Big Pharma contracts dealmaking directory

Chapter 6 Big Pharma dealmaking by technology type

Chapter 7 Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 Big Pharma deals by company A-Z
Appendix 2 Big Pharma deals by stage of development
Appendix 3 Big Pharma deals by deal type
Appendix 4 Big Pharma deals by therapy area
Appendix 5 Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List Of Figures

Figure 1: Big Pharma partnering since 2010
Figure 2: Active Big Pharma dealmaking activity 2010 to 2016
Figure 3: Big Pharma partnering by deal type since 2010
Figure 4: Big Pharma partnering by disease type since 2010
Figure 5: Big Pharma partnering by technology type since 2010
Figure 6: Big Pharma deals with a headline value
Figure 7: Big Pharma deals with an upfront value
Figure 8: Big Pharma deals with a milestone value
Figure 9: Big Pharma deals with a royalty rate value
Figure 10: Top Big Pharma deals by value since 2010
Figure 11: Most active Big Pharma dealmakers 2010 to 2016
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events

Global Pressure Homogenizers Market Research Report 2016

2016 Global Pressure Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Pressure Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Mechanical Homogenizers Market Research Report 2016

2016 Global Mechanical Homogenizers Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Mechanical Homogenizers industry, focusing on the main regions

USD 2850View Report

Global Smart Labels Market Research Report 2016

2016 Global Smart Labels Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Smart Labels industry, focusing on the main regions

USD 2850View Report

Global Big Data Infrastructure Market Research Report 2016

Notes:Production, means the output of Big Data InfrastructureRevenue, means the sales value of Big Data InfrastructureThis report studies Big Data Infrastructure in Global market, especially in North America, Europe, China,

USD 2900View Report

Global Big Data in Manufacturing Market Professional Survey Report 2016

Notes:Production, means the output of Big Data in ManufacturingRevenue, means the sales value of Big Data in ManufacturingThis report studies Big Data in Manufacturing in Global market, especially in North

USD 3500View Report

Global Big Data as a Service Market Report 2016

2016 Global Big Data as a Service Report is a professional and in-depth research report on The worlds major regional Market conditions of The Big Data as a Service industry,

USD 2850View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2995
  • Global Licence    $ 14995
  • Multi User Licence    $ 4495
$ 2995

Reports Details

Published Date : Oct 2016
No. of Pages :1000
Country :Global
Category :Healthcare
Publisher :Wildwood Ventures Ltd.
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment